RVXoldtimer

As you know, the financial statements are out there and Resverlogix is running on fumes, ie., spent. The interim will just be dimmer.

DM's 3 option desperation pitch makes more sense after reviewing the balance sheet, cash position, and cash flow requirements. 

Fortunately, Resverlogix has completed development of promising intellectual property, the clock keeps ticking on patent life for BP, and Resverlogix has a BTD and FDA guidance and parameters to obtain an NDA. This is an extremely demanding business. BP has shareholder demands also - fill the pipeline, generate billions of revenue per annum, find new therapies and cures, cut drug costs and save lives. The time has come for BP to move this therapy to market. Resverlogix has done it's job and will be rewarded handsomely. Who will the new quarterback be?

Tick Tock

Chicagoest